Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NUWE Stock Summary
Top 10 Correlated ETFs
NUWE
In the News
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
MINNEAPOLIS, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year of 2023 on Tuesday, March 5, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference
Nuwellis to share three presentations highlighting the company's Aquadex SmartFlow system Nuwellis to share three presentations highlighting the company's Aquadex SmartFlow system
Here's Why Nuwellis, Inc. (NUWE) Is a Great 'Buy the Bottom' Stock Now
Nuwellis, Inc. (NUWE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Nuwellis, Inc. (NUWE) Q3 2023 Earnings Call Transcript
Nuwellis, Inc. (NASDAQ:NUWE ) Q3 2023 Earnings Conference Call November 7, 2023 9:00 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President and CEO John Jefferies - Chief Medical Officer Rob Scott - CFO Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Anthony Vendetti - Maxim Group Operator Good day, and welcome to the Nuwellis third-quarter 2023 earnings conference call. [Operator Instructions].
Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023
MINNEAPOLIS, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its third quarter 2023 financial results will be released on Tuesday, November 7, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.
Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase
MINNEAPOLIS, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of people with fluid overload, today announced that President and Chief Executive Officer Nestor Jaramillo, Chief Financial Officer Rob Scott, and Chief Medical Officer Dr. John Jefferies, will participate in a fireside chat at the upcoming Gilmartin Group Emerging Growth Showcase on Thursday, September 21, 2023, at 12:00 pm ET.
Why Is Nuwellis (NUWE) Stock Down Today?
Nuwellis (NASDAQ: NUWE ) stock is taking a beating on Monday despite a lack of news concerning the medical device company. In fact, there's really not much in the way of anything to report about Nuwellis stock today.
Nuwellis, Inc. To Announce Second Quarter 2023 Financial Results on August 8, 2023
MINNEAPOLIS, July 18, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its second quarter 2023 financial results will be released on Tuesday, August 8, 2023. The company will host a conference call and webcast at 9:00 AM ET, during which management will discuss the company's financial results and provide a general business overview.
Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference
MINNEAPOLIS, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that Nestor Jaramillo, President and Chief Executive Officer, and Lynn Blake, Chief Financial Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023.
Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
MINNEAPOLIS, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023. The company will host a conference call and webcast at 8:30 AM ET, during which management will discuss the company's financial results and provide a general business overview.
NUWE Financial details
NUWE Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.54K | 451.24 | 114.8 | 49.14 | 4.51 | |
Net income per share | -11.63K | -960.34 | -283.74 | -83.55 | -10.29 | |
Operating cash flow per share | -10.51K | -1K | -259.13 | -87.14 | -9.13 | |
Free cash flow per share | -10.82K | -1.02K | -262.3 | -87.84 | -9.26 | |
Cash per share | 820.92 | 875.5 | 574.9 | 105.3 | 1.93 | |
Book value per share | 1.28K | 989.57 | 376.04 | 71.08 | 1.52 | |
Tangible book value per share | 1.28K | 989.57 | 376.04 | 71.08 | 1.52 | |
Share holders equity per share | 1.28K | 989.57 | 376.04 | 71.08 | 1.52 | |
Interest debt per share | 286.91 | 20.56 | 17.06 | 58.85 | 2 | |
Market cap | 4.02M | 11.49M | 7.87M | 1.86M | 1.14M | |
Enterprise value | 3.19M | -2.6M | -15.16M | -14.89M | -1.68M | |
P/E ratio | -0.22 | -0.73 | -0.4 | -0.13 | -0.06 | |
Price to sales ratio | 0.73 | 1.54 | 0.99 | 0.22 | 0.13 | |
POCF ratio | -0.25 | -0.69 | -0.44 | -0.12 | -0.06 | |
PFCF ratio | -0.24 | -0.68 | -0.43 | -0.12 | -0.06 | |
P/B Ratio | 2.02 | 0.7 | 0.3 | 0.15 | 0.38 | |
PTB ratio | 2.02 | 0.7 | 0.3 | 0.15 | 0.38 | |
EV to sales | 0.58 | -0.35 | -1.91 | -1.74 | -0.19 | |
Enterprise value over EBITDA | -0.18 | 0.15 | 0.8 | 0.89 | 0.1 | |
EV to operating cash flow | -0.19 | 0.16 | 0.85 | 0.98 | 0.09 | |
EV to free cash flow | -0.19 | 0.15 | 0.84 | 0.98 | 0.09 | |
Earnings yield | -4.51 | -1.38 | -2.49 | -7.79 | -17.71 | |
Free cash flow yield | -4.19 | -1.47 | -2.3 | -8.19 | -15.94 | |
Debt to equity | 0.22 | 0.02 | 0.05 | 0.08 | 0.15 | |
Debt to assets | 0.08 | 0.02 | 0.04 | 0.04 | 0.04 | |
Net debt to EBITDA | 0.05 | 0.79 | 1.21 | 1 | 0.16 | |
Current ratio | 1.2 | 5.17 | 8.5 | 4.86 | 2.59 | |
Interest coverage | 0 | 0 | 0 | -1.86 | -5.06 | |
Income quality | 0.9 | 1.05 | 0.91 | 1.04 | 0.89 | |
Dividend Yield | 0 | 0 | 0 | 0 | 2.01 | |
Payout ratio | 0 | 0 | 0 | 0 | -0.11 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.85 | 0.49 | 0.63 | 0.51 | 0.61 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | |
Capex to revenue | -0.09 | -0.04 | -0.03 | -0.01 | -0.03 | |
Capex to depreciation | -2.05 | -0.79 | -0.45 | -0.33 | -0.69 | |
Stock based compensation to revenue | 0.27 | 0.18 | 0.17 | 0.1 | 0.08 | |
Graham number | 18.28K | 4.62K | 1.55K | 365.55 | 18.77 | |
ROIC | -6.28 | -1 | -0.69 | -1.2 | -4.44 | |
Return on tangible assets | -3.23 | -0.79 | -0.64 | -0.59 | -2.07 | |
Graham Net | -536.1 | 782.31 | 538.87 | 48.17 | -0.26 | |
Working capital | 685K | 14.95M | 24.82M | 18.08M | 5.04M | |
Tangible asset value | 1.99M | 16.32M | 25.95M | 12.36M | 2.99M | |
Net current asset value | 424K | 14.84M | 23.66M | 10.45M | 1.43M | |
Invested capital | 0.22 | 0.02 | 0.05 | 0.08 | 0.15 | |
Average receivables | 792.5K | 852K | 827.5K | 1.08M | 1.68M | |
Average payables | 1.31M | 1.29M | 1.26M | 1.83M | 2.31M | |
Average inventory | 1.73M | 2.38M | 2.9M | 2.75M | 2.33M | |
Days sales outstanding | 52.92 | 44.39 | 34.56 | 60.07 | 80.34 | |
Days payables outstanding | 204.18 | 118.32 | 150.47 | 216.32 | 223.83 | |
Days of inventory on hand | 246.58 | 318.94 | 302.53 | 256.41 | 187.81 | |
Receivables turnover | 6.9 | 8.22 | 10.56 | 6.08 | 4.54 | |
Payables turnover | 1.79 | 3.08 | 2.43 | 1.69 | 1.63 | |
Inventory turnover | 1.48 | 1.14 | 1.21 | 1.42 | 1.94 | |
ROE | -9.1 | -0.97 | -0.75 | -1.18 | -6.76 | |
Capex per share | -314.51 | -18.07 | -3.17 | -0.7 | -0.13 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 6.17 | 1.62 | 1.56 | 1.3 | 0.72 | |
Net income per share | -5 | -5.76 | -3.65 | -1.81 | -1.56 | |
Operating cash flow per share | -8.25 | -5.42 | -3.95 | -2.05 | -0.78 | |
Free cash flow per share | -8.3 | -5.51 | -4 | -2.12 | -0.77 | |
Cash per share | 48.3 | 10.74 | 6.7 | 2.65 | 1.07 | |
Book value per share | 32.6 | 12.14 | 8.34 | 4.21 | 0.84 | |
Tangible book value per share | 32.6 | 12.14 | 8.34 | 4.21 | 0.84 | |
Share holders equity per share | 32.6 | 12.14 | 8.34 | 4.21 | 0.84 | |
Interest debt per share | 26.99 | 1.39 | 0.66 | 0.44 | 1.11 | |
Market cap | 4.06M | 5.47M | 3.57M | 2.66M | 2.06M | |
Enterprise value | -12.69M | -5.11M | -4.45M | -1.45M | -763.09K | |
P/E ratio | -0.54 | -0.21 | -0.18 | -0.2 | -0.09 | |
Price to sales ratio | 1.74 | 3 | 1.72 | 1.1 | 0.81 | |
POCF ratio | -1.3 | -0.9 | -0.68 | -0.7 | -0.75 | |
PFCF ratio | -1.29 | -0.88 | -0.67 | -0.67 | -0.76 | |
P/B Ratio | 0.33 | 0.4 | 0.32 | 0.34 | 0.69 | |
PTB ratio | 0.33 | 0.4 | 0.32 | 0.34 | 0.69 | |
EV to sales | -5.43 | -2.8 | -2.14 | -0.6 | -0.3 | |
Enterprise value over EBITDA | 2.84 | 1.02 | 0.9 | 0.47 | 0.22 | |
EV to operating cash flow | 4.06 | 0.84 | 0.85 | 0.38 | 0.28 | |
EV to free cash flow | 4.03 | 0.82 | 0.84 | 0.37 | 0.28 | |
Earnings yield | -0.47 | -1.19 | -1.36 | -1.27 | -2.68 | |
Free cash flow yield | -0.77 | -1.13 | -1.49 | -1.48 | -1.32 | |
Debt to equity | 0.08 | 0.07 | 0.08 | 0.1 | 0.15 | |
Debt to assets | 0.04 | 0.05 | 0.06 | 0.07 | 0.04 | |
Net debt to EBITDA | 3.75 | 2.11 | 1.62 | 1.33 | 0.81 | |
Current ratio | 4.86 | 4.04 | 3.59 | 3.22 | 2.59 | |
Interest coverage | -0.49 | -9.2 | 0 | 0 | -1.03 | |
Income quality | 1.65 | 0.94 | 1.08 | 1.14 | 0.5 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.51 | 0.78 | 0.73 | 0.46 | 0.54 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.02 | 0.01 | 0.03 | -0.01 | |
Capex to revenue | -0.01 | -0.05 | -0.03 | -0.05 | 0.01 | |
Capex to depreciation | -0.27 | -1.14 | -0.78 | -1.44 | 0.33 | |
Stock based compensation to revenue | 0.07 | 0.1 | 0.09 | 0.06 | 0.06 | |
Graham number | 60.58 | 39.66 | 26.16 | 13.09 | 5.44 | |
ROIC | -0.32 | -0.38 | -0.39 | -0.33 | -0.91 | |
Return on tangible assets | -0.08 | -0.35 | -0.31 | -0.29 | -0.56 | |
Graham Net | 22.1 | 8.55 | 5.02 | 1.92 | -0.15 | |
Working capital | 18.08M | 12.5M | 9.92M | 6.65M | 5.04M | |
Tangible asset value | 12.36M | 13.66M | 11.07M | 7.84M | 2.99M | |
Net current asset value | 10.45M | 11.8M | 9.27M | 6.05M | 1.43M | |
Invested capital | 0.08 | 0.07 | 0.08 | 0.1 | 0.15 | |
Average receivables | 1.25M | 1.35M | 1.24M | 1.3M | 1.69M | |
Average payables | 1.9M | 2.38M | 2.42M | 2.01M | 2.04M | |
Average inventory | 2.79M | 2.7M | 2.74M | 2.53M | 2.17M | |
Days sales outstanding | 54.1 | 64.12 | 51.01 | 53.17 | 68.83 | |
Days payables outstanding | 200.45 | 299.29 | 224.13 | 149.01 | 184.18 | |
Days of inventory on hand | 237.59 | 325.14 | 265.05 | 203.92 | 154.54 | |
Receivables turnover | 1.66 | 1.4 | 1.76 | 1.69 | 1.31 | |
Payables turnover | 0.45 | 0.3 | 0.4 | 0.6 | 0.49 | |
Inventory turnover | 0.38 | 0.28 | 0.34 | 0.44 | 0.58 | |
ROE | -0.15 | -0.47 | -0.44 | -0.43 | -1.84 | |
Capex per share | -0.05 | -0.09 | -0.05 | -0.06 | 0.01 |
NUWE Frequently Asked Questions
What is Nuwellis, Inc. stock symbol ?
Nuwellis, Inc. is a US stock , located in Eden prairie of Mn and trading under the symbol NUWE
What is Nuwellis, Inc. stock quote today ?
Nuwellis, Inc. stock price is $0.3938 today.
Is Nuwellis, Inc. stock public?
Yes, Nuwellis, Inc. is a publicly traded company.